表紙
市場調査レポート

脈絡膜新生血管:パイプライン製品の分析

Choroidal Neovascularization - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213111
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
脈絡膜新生血管:パイプライン製品の分析 Choroidal Neovascularization - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 74 Pages
概要

脈絡膜新生血管膜(NCVM)とは、網膜の下部(脈絡膜)に新たに発生する血管で、視力低下を引き起こします。主な症状には、痛みを伴わない視野喪失や、変視野、色覚異常などが挙げられます。主な治療法として、抗VEGF(血管内皮増殖因子)抗体やレーザー光凝固術、光力学的療法などがあります。

当レポートでは、世界各国での脈絡膜新生血管治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

脈絡膜新生血管の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

脈絡膜新生血管:企業で開発中の治療薬

脈絡膜新生血管:大学/機関で研究中の治療薬

脈絡膜新生血管:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

脈絡膜新生血管:企業で開発中の製品

脈絡膜新生血管:大学/機関で研究中の製品

脈絡膜新生血管の治療薬開発に従事している企業

  • Affitech A/S
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Iconic Therapeutics, Inc.
  • Mabion SA
  • Navigen Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • Promedior, Inc.
  • 三和化学研究所

脈絡膜新生血管:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

脈絡膜新生血管:最近のパイプライン動向

脈絡膜新生血管:休止中のプロジェクト

脈絡膜新生血管:開発が中止された製品

脈絡膜新生血管:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7866IDB

Summary

Global Markets Direct's, 'Choroidal Neovascularization - Pipeline Review, H1 2016', provides an overview of the Choroidal Neovascularization pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization
  • The report reviews pipeline therapeutics for Choroidal Neovascularization by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Choroidal Neovascularization therapeutics and enlists all their major and minor projects
  • The report assesses Choroidal Neovascularization therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Choroidal Neovascularization

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Choroidal Neovascularization Overview
  • Therapeutics Development
    • Pipeline Products for Choroidal Neovascularization - Overview
    • Pipeline Products for Choroidal Neovascularization - Comparative Analysis
  • Choroidal Neovascularization - Therapeutics under Development by Companies
  • Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes
  • Choroidal Neovascularization - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Choroidal Neovascularization - Products under Development by Companies
  • Choroidal Neovascularization - Products under Investigation by Universities/Institutes
  • Choroidal Neovascularization - Companies Involved in Therapeutics Development
    • Affitech A/S
    • F. Hoffmann-La Roche Ltd.
    • Genentech, Inc.
    • Iconic Therapeutics, Inc.
    • Mabion SA
    • Navigen Pharmaceuticals, Inc.
    • Noxxon Pharma AG
    • Promedior, Inc.
    • Sanwa Kagaku Kenkyusho Co., Ltd.
  • Choroidal Neovascularization - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AP-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Doxarubicin Pegylated - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hI-con1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-30D8 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Netrin-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-9405 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NOXD-20 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGN-635 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRM-167 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-7716 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SK-1011 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Choroidal Neovascularization - Recent Pipeline Updates
  • Choroidal Neovascularization - Dormant Projects
  • Choroidal Neovascularization - Discontinued Products
  • Choroidal Neovascularization - Product Development Milestones
    • Featured News & Press Releases
      • Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance
      • Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
      • May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Choroidal Neovascularization, H1 2016
  • Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Choroidal Neovascularization - Pipeline by Affitech A/S, H1 2016
  • Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Choroidal Neovascularization - Pipeline by Genentech, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Iconic Therapeutics, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Mabion SA, H1 2016
  • Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2016
  • Choroidal Neovascularization - Pipeline by Promedior, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H1 2016
  • Choroidal Neovascularization - Dormant Projects, H1 2016
  • Choroidal Neovascularization - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Choroidal Neovascularization, H1 2016
  • Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top